Liquidia Corporation (LQDA) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to the Liquidia Corporation second quarter 2026 financial results and corporate update conference call. My name is Daniel and I will be your operator today. All participants are currently in listen only mode. Following the presentation, we will conduct a question and answer session. Instructions for joining the queue will be provided at that time. Please note that today's call is being recorded. I'll now turn the call over to Jason Adair, Liquidia's chief business officer. Thank you and good morning, everyone. It's my pleasure to welcome you to our second quarter 2026 financial result and corporate update call. Joining me today are Dr. Roger Jeffs, Chief Executive Officer, Michael Kaseta, Chief Operating Officer and Chief Financial Officer, Dr. Rajeev Saggar, Chief Medical Officer, Scott Moomaw, Chief Commercial Officer, and Rusty Schundler, General Counsel. Before we begin, please note that today's discussion will include forward-looking statements, including statements regarding future results, product performance, and ongoing clinical or commercial activities. These statements are subject to risks and uncertainties that may cause actual results to differ materially. For further information, please refer to our filings with the SEC, which are available on our website. Please also note that our earnings release and our commentary include non-gap financial measures. Reconciliations of these non-gap financial measures to the most comparable gap measures can be found in our earnings press release. With that, I'll turn the call over to Roger. Thanks, Jason, and good morning, everyone. We're delighted to share our business results and clinical progress with you today. One year ago, we launched Utrepia and believed the medical community would find...